Pleural effusion is an accumulation of fluid in the pleural space, between the two layers of pleura. This fluid can be transudative or exudative. Transudative pleural effusion is the most common type of pleural effusion and is caused by an imbalance between hydrostatic and oncotic pressures in the pleural space. This imbalance leads to the accumulation of fluid in the pleural space. It is important for doctors to understand the causes, diagnosis, and treatment of transudative pleural effusion in order to properly treat patients with this condition.
Transudative pleural effusion is usually caused by an underlying systemic disorder. Common causes include congestive heart failure, cirrhosis, hypoalbuminemia, and nephrotic syndrome. Other causes include pulmonary embolism, hypothyroidism, and lupus. In some cases, the cause of transudative pleural effusion is unknown, and this is known as idiopathic transudative pleural effusion.
The diagnosis of transudative pleural effusion is based on the results of a physical examination, chest x-ray, and pleural fluid analysis. A physical examination can provide clues to the underlying cause of the effusion, such as the presence of edema or ascites. Chest x-ray can help to identify the presence and extent of pleural effusion. Pleural fluid analysis can help to distinguish between transudative and exudative effusions. The pleural fluid analysis includes measuring the pleural fluid protein, glucose, and lactate dehydrogenase levels. The pleural fluid protein level is typically lower than the serum protein level in transudative effusions. The pleural fluid glucose level is typically lower than the serum glucose level. The pleural fluid lactate dehydrogenase level is typically lower than the serum lactate dehydrogenase level.
The treatment of transudative pleural effusion depends on the underlying cause. If the cause is congestive heart failure, then treatment may include diuretics and other medications to reduce the fluid accumulation. If the cause is cirrhosis, then treatment may include medications to reduce the ascites. If the cause is hypoalbuminemia, then treatment may include intravenous albumin. In some cases, the cause of transudative pleural effusion is unknown and the effusion may resolve on its own. In these cases, the patient may be monitored with periodic chest x-rays to ensure that the effusion is not progressing.
Transudative pleural effusion is a common condition that is caused by an underlying systemic disorder. It is important for doctors to understand the causes, diagnosis, and treatment of transudative pleural effusion in order to properly treat patients with this condition. Treatment may include medications to reduce the fluid accumulation or to address the underlying cause. In some cases, the effusion may resolve on its own. With proper diagnosis and treatment, patients with transudative pleural effusion can be managed effectively.
1.
Even when they are not paying attention, children are still learning.
2.
Survivors of high-risk neuroblastoma face substantial late effects of modern therapies
3.
Kate Middleton Reaches Cancer Treatment Milestone
4.
Pulled Myeloma Drug Improves Survival in Trial
5.
Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.
1.
Breast Cancer Secrets: AI-Powered Precision Medicine
2.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
3.
Surprising Symptoms of Prostate Cancer: What You Need to Know
4.
Empowering Lung Cancer Diagnosis Through the Synergy of Advanced Technologies and Artificial Intelligence
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation